Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SWS Hemodialysis Care CoSHSE:688410 +0.38%88 EBITDA Margin % is 27.08% as of Mar. 2026, which is 91% above its 10-year median of 14.19. GuruFocus rates SHSE:688410 with a GF Score™ of 88/100 and a GF Value™ of ¥15.44 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, SWS Hemodialysis Care Co ranks better than 78.9% on this metric.
SWS Hemodialysis Care Co (SHSE:688410) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SWS Hemodialysis Care Co EBITDA Margin % Related Terms
SWS Hemodialysis Care Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688410 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, SWS Hemodialysis Care Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SWS Hemodialysis Care Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SWS Hemodialysis Care Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SWS Hemodialysis Care Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SWS Hemodialysis Care Co (SHSE:688410) has a EBITDA Margin % of 27.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SWS Hemodialysis Care Co and its competitors. This is 91% above median its historical median of 14.19. According to the industry distribution chart, SWS Hemodialysis Care Co ranks #172 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 21.1%.
Is SWS Hemodialysis Care Co's EBITDA Margin % too high?
SWS Hemodialysis Care Co's current EBITDA Margin % of 27.08% is 91% above median its 10-year median of 14.19. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. SWS Hemodialysis Care Co's value of 27.08% is 260.1% above this industry median. Based on the distribution chart, SWS Hemodialysis Care Co ranks #172 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, SWS Hemodialysis Care Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SWS Hemodialysis Care Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SWS Hemodialysis Care Co ranks #172 out of 815 companies for EBITDA Margin %. This places SWS Hemodialysis Care Co in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.52. SWS Hemodialysis Care Co's value of 27.08% is 260.1% above this benchmark. While the company's 10-year median is 14.19 vs. the industry median of 7.52, SWS Hemodialysis Care Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SWS Hemodialysis Care Co's current EBITDA Margin % of 27.08% is 260.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SWS Hemodialysis Care Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SWS Hemodialysis Care Co's current EBITDA Margin % is 27.08%, which is 91% above median its own 10-year median of 14.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SWS Hemodialysis Care Co stock overvalued right now?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co (SHSE:688410) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥15.44, compared to a current price of ¥10.59 — trading 31.4% below its estimated fair value. The current EBITDA Margin % is 27.08%, which is 91% above median its 10-year median of 14.19 and 260.1% above the Medical Devices & Instruments industry median of 7.52. SWS Hemodialysis Care Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SWS Hemodialysis Care Co (SHSE:688410), the current EBITDA Margin % is 27.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SWS Hemodialysis Care Co (SHSE:688410) Overvalued in 2026?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co stock appears to be undervalued.
The current stock price of ¥10.59 is trading 31.4% below its estimated GF Value™ of ¥15.44.
GuruFocus considers SWS Hemodialysis Care Co to be Significantly Undervalued.
Key valuation signals for SHSE:688410:
EBITDA Margin %: 27.08% (91% above median its 10-year median of 14.19)
GF Value™: ¥15.44 vs. price of ¥10.59 (31.4% below fair value)
Industry Position: 260.1% above the Medical Devices & Instruments median (#172 of 815)
No single metric tells the full story. See the SHSE:688410 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SWS Hemodialysis Care Co Ltd along with its subsidiaries is engaged in the field of blood purification. Its focused on patients welfare and ensuring the delivery of safe and effective products and services. The group operates through four segments: Blood Purification Equipment, Blood Purification Consumables, advanced Hemodialysis Management System, and Chain Dialysis centers. The organization is delivering medical solutions for patients with chronic kidney disease (CKD). Its products include Blood Purification Equipment Dialysis, Disposables Dialysis Center, Intelligent Management System, and Chain Dialysis centers. SWS is committed to enhancing patient wellness by prioritizing care through advanced integrated blood purification technologies.
88GF Score
Get the complete analysis for SHSE:688410
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688410 has been successfully added to your 
